IQInvest research note
12 OCT 2026 · 08:07 ET
BMY
Bristol-Myers Squibb Company
$59.12
-$0.46 (-0.77%)down -0.77%
12 October 2026 · delayed 15+ min
D+
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Bristol-Myers Squibb Company earns a D+ on good profit margins (>10%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and MACD bearish (negative histogram). Reasonable investment with moderate upside potential.
Adjusted for Moderate investors, Medium-term investors 6.0% suggested allocation Change these
IQ-BMY-20261012engine v1 · 7-category weighted scorecard